A New Medicine for Pancreatic Cancer
A New Medicine for Pancreatic Cancer
一種新型胰臟癌藥物
Introduction
A company called Revolution Medicines has a new drug. It helps people with a bad type of pancreatic cancer.
一家名為 Revolution Medicines 的公司研發了一款新藥，可幫助患有惡性胰臟癌的患者。
Main Body
The drug is called daraxonrasib. It stops a bad protein in the body. In a big test, patients lived longer. They lived about 13 months instead of 6 months. Some patients had skin rashes or felt sick, but they felt better than with old medicines.
這種藥物稱為 daraxonrasib，能阻止體內一種有害蛋白質的運作。在一項大型測試中，患者的生存期延長了，從 6 個月增加到約 13 個月。部分患者出現皮疹或感到不適，但與使用舊藥相比，他們的狀況有所改善。
Some doctors think this drug is very good. They say it is not fair to give new patients old medicine in tests. They want the government to give the drug to more people faster.
部分醫生認為這種藥物非常有效。他們表示，在測試中讓新患者使用舊藥是不公平的。他們希望政府能更快地將此藥物提供給更多患者。
The boss of the company, Mark Goldsmith, wants to help. Some patients can get the drug now. However, some people worry the company cannot make enough of the medicine for everyone.
公司執行長 Mark Goldsmith 希望提供幫助，目前已有部分患者可以獲得該藥物。然而，有些人擔心公司無法生產足夠的藥量以供應所有人。
Conclusion
The government may soon allow this drug for many patients. Doctors are talking about using it as the first treatment.
政府可能很快會允許許多患者使用這種藥物。醫生們正在討論將其作為首選治療方案。
Vocabulary Learning
🕰️ Comparing Time: 'Instead of'
In the story, we see: "They lived about 13 months instead of 6 months."
When you want to say "not A, but B," use instead of. It is a great way to show a change or a better choice.
Easy Examples:
- I drink water instead of soda.
- I walk to school instead of taking the bus.
- He uses a new drug instead of an old one.
🛠️ Word Building: 'Better Than'
Look at this phrase: "they felt better than with old medicines."
To compare two things, we use Better Than.
The Pattern: [Thing 1] + is/feels + better than + [Thing 2].
- This medicine is better than the old one.
- Today feels better than yesterday.
- My English is better than last month.
Vocabulary Learning
The Development and Approval Process of Daraxonrasib for Pancreatic Cancer
Daraxonrasib 治療胰臟癌的研發與審批過程
Introduction
Revolution Medicines is currently seeking official approval for daraxonrasib, a targeted treatment that has shown a significant increase in survival rates for patients with advanced pancreatic cancer.
Revolution Medicines 目前正尋求 Daraxonrasib 的正式批准，這是一種能顯著提高晚期胰臟癌患者生存率的標靶治療。
Main Body
Daraxonrasib works by blocking the KRAS protein, a genetic mutation found in more than 90% of pancreatic tumors. In the past, this protein was considered impossible to target with medicine. In a Phase 3 clinical trial with 500 patients, the drug increased average survival from 6.7 to 13.2 months and reduced the risk of death by 60%. Although some patients experienced side effects such as nausea and skin rashes, the overall quality of life was better than with standard chemotherapy.
Daraxonrasib 的作用原理是阻斷 KRAS 蛋白，這種基因突變存在於超過 90% 的胰臟腫瘤中。過去，這種蛋白被認為無法透過藥物進行標靶治療。在一項包含 500 名患者的第三期臨床試驗中，該藥物將平均生存期從 6.7 個月提高到 13.2 個月，並將死亡風險降低了 60%。儘管部分患者出現了如噁心和皮膚紅疹等副作用，但整體生活品質優於標準化療。
However, a debate has started regarding the ethics of using the drug as a first-line treatment. Rick Pazdur, a former FDA official, argued that because the drug is so effective, it might be unfair to give some newly diagnosed patients only chemotherapy in a clinical trial. To solve this, he suggested a 'reverse accelerated approval' process. This would allow the drug to be approved based on how quickly tumors shrink, while long-term survival is checked using other data.
然而，關於將該藥物作為一線治療的倫理問題已引起爭論。前 FDA 官員 Rick Pazdur 主張，由於該藥物非常有效，在臨床試驗中讓部分新診斷的患者僅接受化療可能是不公平的。為了擬定對策，他建議採取「反向加速審批」流程。這將允許根據腫瘤縮小速度來批准藥物，而長期生存率則透過其他數據進行驗證。
Mark Goldsmith, the CEO of Revolution Medicines, stated that the company is open to these flexible rules, although they are continuing their current trials. Meanwhile, some patients can already access the drug through a special program, but there are concerns about whether the company can produce enough of the medicine to meet the high demand.
Revolution Medicines 的執行長 Mark Goldsmith 表示，公司對這些靈活的規則持開放態度，儘管他們將繼續進行目前的試驗。與此同時，部分患者已能透過特別計畫獲取該藥物，但外界擔心公司是否能生產足夠的藥物以滿足高需求。
Conclusion
Daraxonrasib is expected to become the standard second-line treatment if the FDA approves it, and discussions continue regarding its use as a primary treatment.
若 FDA 批准，Daraxonrasib 預計將成為標準的二線治療，而關於將其作為首選治療的討論仍在持續。
Vocabulary Learning
🚀 The 'Nuance Jump': From Basic Facts to Complex Ideas
As an A2 student, you usually say: "The drug is good. Some people feel sick." To reach B2, you must connect these ideas using Contrast and Concession. This is the secret to sounding professional and fluent.
🔍 The Linguistic Key: "Although" vs "However"
Look at these two segments from the text:
- "Although some patients experienced side effects... the overall quality of life was better..."
- "However, a debate has started regarding the ethics..."
The B2 Difference:
- Although is a 'glue' word. It connects two opposing ideas in one single sentence. It tells the reader: "I am giving you a negative point, but the main point is actually positive."
- However is a 'pivot' word. It starts a new sentence to change the direction of the whole conversation. It is a signal that the topic is shifting from the results of the drug to the ethics of the drug.
🛠️ Upgrade Your Speech
Stop using 'But' for everything. Try these B2 patterns based on the article:
| A2 Level (Basic) | B2 Level (Bridge) | Why it's better |
|---|---|---|
| The drug works, but it has side effects. | Although the drug has side effects, it is very effective. | Shifts focus to the success. |
| It is expensive, but patients want it. | Patients want the drug; however, there are concerns about supply. | Creates a formal, academic tone. |
💡 Pro Tip: The "Flexible" Modifier
Notice the phrase "open to these flexible rules." In A2, we use simple adjectives (good, bad, big). B2 students use precise modifiers. Instead of saying "the rules can change," saying "flexible rules" shows you can describe the nature of a system, not just its state.
Vocabulary Learning
Regulatory and Clinical Trajectory of Daraxonrasib in Metastatic Pancreatic Adenocarcinoma Treatment
Daraxonrasib 治療轉移性胰臟腺癌的監管與臨床路徑
Introduction
Revolution Medicines is seeking regulatory approval for daraxonrasib, a targeted therapy demonstrating significant survival benefits for patients with metastatic pancreatic cancer.
Revolution Medicines 正尋求 daraxonrasib 的監管批准，這是一款為轉移性胰臟癌患者展現顯著生存益處的標靶療法。
Main Body
The pharmacological mechanism of daraxonrasib involves the inhibition of the KRAS protein, a genetic mutation present in over 90% of pancreatic tumors and previously considered therapeutically inaccessible. Rather than direct binding to KRAS, the agent attaches to cyclophilin A to disrupt the protein's signaling capacity. In a Phase 3 clinical trial involving 500 pre-treated patients, the agent increased overall survival from 6.7 to 13.2 months and reduced mortality risk by 60%. While adverse effects included stomatitis, nausea, and a high incidence of skin rash (86%), the therapy demonstrated a superior quality-of-life profile compared to standard chemotherapy.
Daraxonrasib 的藥理機制涉及抑制 KRAS 蛋白，這種基因突變存在於 90% 以上的胰臟腫瘤中，且先前被認為無法透過藥物治療。該藥劑並非直接與 KRAS 結合，而是附著於 cyclophilin A 以破壞蛋白質的信號傳導能力。在一項涉及 500 名經過預處理患者的第三期臨床試驗中，該藥劑將總生存期從 6.7 個月提高至 13.2 個月，並降低了 60% 的死亡風險。雖然不良反應包括口腔炎、噁心以及高發率的皮疹（86%），但與標準化療相比，該療法展現出更優質的生活品質。
Regarding the transition to first-line therapy, a significant ethical complication has emerged concerning clinical equipoise. Former FDA official Rick Pazdur posited that the established efficacy of daraxonrasib in second-line settings may render the randomization of newly diagnosed patients to chemotherapy-only control arms ethically untenable. To mitigate this, Pazdur proposed a 'reverse accelerated approval' framework, wherein regulatory authorization would be based on rapid tumor response data, with long-term survival validated via external control arms.
關於轉向一線療法，出現了一個關於臨床均勢的重大倫理複雜問題。前 FDA 官員 Rick Pazdur 認為，daraxonrasib 在二線治療中已確立的療效，可能使新診斷患者被隨機分配到僅含化療的對照組在倫理上變得不可行。為了緩解這一點，Pazdur 提出了一種「反向加速批准」框架，其中監管授權將基於快速腫瘤反應數據，而長期生存率則透過外部對照組驗證。
Revolution Medicines CEO Mark Goldsmith has expressed openness to regulatory flexibility while maintaining the progression of the current Phase 3 trial. Concurrently, the drug is available via an expanded access program, though patient concerns persist regarding the manufacturing capacity of the developer to meet anticipated demand.
Revolution Medicines 執行長 Mark Goldsmith 表示，在維持目前第三期試驗進展的同時，對於監管靈活性持開放態度。與此同時，該藥物已透過擴大獲取計劃提供，儘管患者仍擔心開發商的生產能力是否能滿足預期需求。
Conclusion
Daraxonrasib is positioned to become the second-line standard of care pending FDA approval, with ongoing discussions regarding its potential expansion to first-line treatment.
在等待 FDA 批准期間，Daraxonrasib 將被定位為二線標準治療，目前正就其潛在擴展至一線治療進行討論。
Vocabulary Learning
The Architecture of Nuance: 'Ethical Untenability' and the Logic of C2 Precision
At the B2/C1 level, a student might describe a situation as "wrong," "problematic," or "unacceptable." However, the bridge to C2 mastery lies in the ability to utilize high-precision descriptors that encapsulate a complex philosophical or systemic state within a single adjective.
◈ The Pivot: Ethically Untenable
In the text, the phrase "render the randomization... ethically untenable" is the linguistic crown jewel.
Analysis:
- Untenable (adj.): Literally, a position that cannot be defended. In an academic or regulatory context, it transcends "wrong" to mean "logically and morally impossible to sustain under scrutiny."
- The C2 Synthesis: The author does not say the trial is bad; they argue the position of the trial is untenable. This shifts the focus from a moral judgment to a structural impossibility.
◈ Lexical Sophistication: Precision Pairing
Observe the symbiotic relationship between these high-level collocations found in the text:
| B2/C1 Approximation | C2 Masterclass Equivalent | Semantic Shift |
|---|---|---|
| Impossible to treat | Therapeutically inaccessible | From "can't do it" "out of reach for current medical science" |
| Suggested a plan | Posited a framework | From "gave an idea" "proposed a theoretical structure for validation" |
| Make something happen | Render [something] [adj] | From "make" "cause to become/be perceived as" |
◈ Syntactic Mastery: The 'Abstract Subject' Construction
C2 English frequently employs the Abstract Subject to maintain a formal, objective distance.
"A significant ethical complication has emerged concerning clinical equipoise."
Instead of saying "Scientists are worried about the ethics," the author makes the "complication" the subject. This removes the human agent and elevates the discourse to a systemic level.
Pro Tip for C2 Transition: Stop centering your sentences around people (I, they, researchers). Start centering them around concepts (complications, trajectories, frameworks, capacities). This is the hallmark of scholarly English.